Advances in the delivery of antisense oligonucleotides for combating bacterial infectious diseases'

被引:61
|
作者
Xue, Xiao-Yan [1 ]
Mao, Xing-Gang [2 ]
Zhou, Ying [3 ]
Chen, Zhou [1 ]
Hu, Yue [1 ]
Hou, Zheng [1 ]
Li, Ming-Kai [1 ]
Meng, Jing-Ru [1 ]
Luo, Xiao-Xing [1 ]
机构
[1] Fourth Mil Med Univ, Sch Pharm, Dept Pharmacol, Xian, Shaanxi, Peoples R China
[2] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian, Shaanxi, Peoples R China
[3] Xian Med Univ, Dept Pharmacol, Xian, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Antisense oligonucleotides; Multidrug resistance; Drug delivery; Cell penetrating peptide; Nanoparticle; CELL-PENETRATING PEPTIDE; RESISTANT STAPHYLOCOCCUS-AUREUS; MORPHOLINO OLIGOMER CONJUGATE; LOCKED NUCLEIC-ACID; ESCHERICHIA-COLI; GENE-EXPRESSION; DNA NANOSTRUCTURES; PURE CULTURE; IN-VITRO; INTRACELLULAR DELIVERY;
D O I
10.1016/j.nano.2017.12.026
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Discovery and development of new antibacterial drugs against multidrug resistant bacterial strains have become more and more urgent. Antisense oligonucleotides (ASOs) show immense potential to control the spread of resistant microbes due to its high specificity of action, little risk to human gene expression, and easy design and synthesis to target any possible gene. However, efficient delivery of ASOs to their action sites with enough concentration remains a major obstacle, which greatly hampers their clinical application. In this study, we reviewed current progress on delivery strategies of ASOs into bacteria, focused on various non-virus gene vectors, including cell penetrating peptides, lipid nanoparticles, bolaamphiphile-based nanoparticles, DNA nanostructures and Vitamin B12. The current review provided comprehensive understanding and novel perspective for the future application of ASOs in combating bacterial infections. (c) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:745 / 758
页数:14
相关论文
共 50 条
  • [21] Delivery of antisense oligonucleotides to neuroblastoma cells
    Skalko-Basnet, N
    Tohda, M
    Watanabe, H
    NEUROREPORT, 2000, 11 (14) : 3117 - 3121
  • [22] Topical and transdermal delivery of antisense oligonucleotides
    Brand, RM
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2001, 3 (03) : 244 - 248
  • [23] Oral delivery of siRNA and antisense oligonucleotides
    Akhtar, Saghir
    JOURNAL OF DRUG TARGETING, 2009, 17 (07) : 491 - 495
  • [24] Oral delivery of antisense oligonucleotides in man
    Tillman, Lloyd G.
    Geary, Richard S.
    Hardee, Gregory E.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (01) : 225 - 236
  • [25] Targeted delivery of antisense oligonucleotides in cancer
    Pastorino, F
    Stuart, D
    Ponzoni, M
    Allen, TM
    JOURNAL OF CONTROLLED RELEASE, 2001, 74 (1-3) : 69 - 75
  • [26] Polymersome delivery of siRNA and antisense oligonucleotides
    Discher, Dennis E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [27] Nanoparticulate systems for the delivery of antisense oligonucleotides
    Lambert, G
    Fattal, E
    Couvreur, P
    ADVANCED DRUG DELIVERY REVIEWS, 2001, 47 (01) : 99 - 112
  • [28] Development of delivery systems for antisense oligonucleotides
    Takakura, Y
    Mahato, RI
    Nomura, T
    Sawai, K
    Yoshida, M
    Kanamaru, T
    Hashida, M
    ADVANCED BIOMATERIALS IN BIOMEDICAL ENGINEERING AND DRUG DELIVERY SYSTEMS, 1996, : 357 - 358
  • [29] Aspects of the transport and delivery of antisense oligonucleotides
    Juliano, RL
    Yoo, H
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2000, 2 (03) : 297 - 303
  • [30] Antisense oligonucleotides for the treatment of neurodegenerative diseases
    Zhao, Hien T.
    Kordasiewicz, Holly
    Norris, Dan
    Smith, Anne
    Lane, Roger
    Bennett, C. Frank
    Swayze, Eric
    PRION, 2019, 13 : 94 - 95